Acceleron Pharma is focused on developing therapeutics for metabolic and musculoskeletal diseases affecting millions of people. The company was founded with an interesting intellectual property portfolio and a deep knowledge of the largely untapped TGF-beta superfamily. The company has multiple programs in development. Furthermore, the company has created a proprietary discovery and development platform to deepen its pipeline and advance product candidates rapidly and efficiently.
